[Featured Stock] Nanos Soars on News of LNP Production Contract for Moderna Use
[Asia Economy Reporter Jang Hyowon] Nanos is surging on news that it has signed an exclusive agreement with Germany's global bio company CordenPharma for the production and supply of LNP (lipid nanoparticles and peptide drugs) in Korea.
As of 12:09 PM on the 25th, Nanos is trading at 6,780 KRW, up 12.07% from the previous day.
According to industry sources, CordenPharma has signed an exclusive agreement with Nanos for the production and supply of the LNP-related CDMO platform in Korea.
LNP is a cutting-edge formulation technology recently well known for being used in the mRNA vaccines of Moderna and Pfizer against COVID-19. LNP is known to help the injected mRNA reach the target cells stably within the body.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- [Exclusive] K-Growth CEO Appointment Process Nears Completion... KDB Candidate Excluded
- The Unexpected Story of an American Man Who Won the Lottery 18 Times in 29 Years: "My Real Luck Is My Wife"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Meanwhile, CordenPharma has been exclusively supplying lipid raw materials necessary for Moderna's mRNA product production since 2016, and it is estimated that its sales exceeded 500 million USD (approximately 560 billion KRW) last year due to a surge in supply to Moderna.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
